
Solution Key- 7.013 Finals (5 / 19 / 09)

Question 1

Familial adenomatous polyposis (FAP) affects nearly 1/8000 people in the USA. Patients having FAP are genetically **predisposed** to colon cancer. Mutations in the APC gene have been identified as the probable cause of FAP.

(a) The following diagram represents the gel electrophoretic profiles of both the PCR amplified APC DNA (top panel) and APC protein (bottom panel) isolated from white blood cells (WBCs) and colon cancer cells of two individual patients. (*A profile of the APC DNA and APC protein in a normal individual is provided as a reference. Please note the intensity of the bands while answering this question*).



i. Explain why in the normal individual, the APC protein is detected only in colon cells even though the APC DNA is present in both colon cells and WBCs.

All **somatic cells in an individual have the same DNA** and hence the same set of genes. However, each cell type in an individual expresses only **specific set of genes** which regulate their shape, size and functions.

ii. One of these two individuals **does not** have FAP but still develops colon cancer. Given the data above, which individual would this be? Explain how this individual got colon cancer.

Individual #2 does not have FAP but sporadically develops colon cancer. This individual undergoes a spontaneous somatic mutation of both alleles of APC genes in colon cells producing a non-functional APC protein that leads to colon cancer.

iii. Complete the following table based on the information provided in the gel profile above. (Use the symbols '+' to represent the wild-type allele of the APC gene, '-' to represent the loss of function mutation and 'M' to represent the gain of function mutation. The genotype of the APC gene in a normal individual is provided as a reference).


Individuals	Genotype of APC gene		Is the genotype of WBC different from
	WBC	Colon cells or	colon cancer cells? If yes, explain why.
		Colon cancer	
		cells	
Normal	+/+	+/+	
#1	+/-	-/-	Yes, APC gene shows loss of heterozygosity
#2	+/+	-/-	-do-

Question 1 continued

(b) Vincristine is an inhibitor of microtubule assembly and is used as an important chemotherapeutic drug. Explain how the disruption of microtubule assembly may prevent cancer cell growth.

Microtubules are required for the formation of **spindle fibers during cell division** that are required to pull the sister chromatids towards the two poles. If these are disrupted the sister chromatids fail to separate properly thus inhbiting cell division and making the cell non-viable. Thus the growth of tumor will be inhibited.

(c) During drug screening you identify two compounds A and B that have the potential to kill colon cancer cells and normal cells as shown by the following graph.



Which of these two compounds is a better candidate for colon cancer treatment? Explain why.

Compound A will be a better choice since it has a **larger therapeutic index** i.e. The effective concentration of compound A that is required to kill the cancer cells is far less compared to the concentration needed to kill the normal cells.

(d) Many patients show signs of severe anemia as a side effect of chemotherapy and are prescribed erythropoietin (EPO). EPO is a secreted protein, produced by the kidney, which binds to its receptor on erythroid precursor cells and stimulates the formation of red blood cells (RBCs). Four different mutations are described below. For each mutation, list whether the RBC production would **increase**, **decrease or not change** in an individual that was homozygous for this mutation as compared to the wild-type situation. Briefly explain your reasoning for each mutation.

i. A mutation in the EPO gene, which results in deletion of the signal sequence of the EPO protein.

EPO will **not be** secreted by the kidney cells. RBC production will **decrease**.

ii. A mutation in the EPO receptor, which results in the deletion of its transmembrane domain.

EPO receptors will not be expressed on the surface of erythroid precursor cells and will therefore not available to bind to the EPO secreted by kidney. RBC production will decrease.

iii. A mutation in the EPO receptor that results in the deletion of its cytoplasmic domain. *EPO receptor will bind to the EPO. However in the absence of the cytoplasmic domain the signal will not be propagated to the other component in the erythroid precursor cells that are required to promote cell proliferation. RBC production will decrease.*

iv. A mutation that results in a constitutively active promoter for the EPO gene. EPO will **be always be produced** and available to bind to the EPO receptors on erythroid precursor cells to **increase** RBC production.

You are studying two characteristics in a plant; growth (slow or fast) and seed size (small or large). You cross a true-breeding plant with large seeds and slow growth to a true-breeding plant with small seeds and fast growth. All of the resulting F1 plants have small seeds and grow slowly.

(a) What are the genotypes of the true breeding parental plants? Use the nomenclature outlined below.

- In each case, use the uppercase letter for the allele associated with the dominant phenotype and the lowercase letter for the allele associated with the recessive phenotype.
- For the seed size (i.e. large or small) use D or d to designate the alleles.
- For the growth (i.e. slow or fast) use G or g to designate the alleles.

Parents	Genotypes
Large seeds and slow growth	ddGG
Small seeds and fast growth	DDgg


(b) You then cross two of the F1 plants that have small seeds and grow slowly. If these two genes are unlinked, about how many total offspring will you need to obtain 100 plants that have large seeds and are fast growing?

1600

(c) You find that the two genes are linked, and plan to determine the map distance between the gene that regulates seed size and the gene that regulates plant growth rate. You test cross an F1 plant to a plant with large seeds that is fast growing. What are the genotypes and phenotypes associated with the non-recombinant and recombinant progeny?


Progeny	Phenotypes	Genotypes
Recombinant	Small and slow	DdGg
	Large and fast	ddgg
Non-recombinant	Small and fast	Ddgg
	Large and slow	ddGg

(a) For the pedigree below, identify the most likely mode of inheritance and state the genotypes of the numbered individuals in the following tables. (*Note: The filled squares or circles represent the abnormal phenotype. Assume that the unaffected people marrying into the family are homozygous for the wild type allele of the gene. Use the letter "A" for the allele associated with the dominant phenotype, "a" for the allele associated with the recessive phenotype. Assume complete penetrance).*



Mode of inheritance:		
Individuals	Genotypes	
#1	AA	
#2	aa	
#3	Aa	

(b) Individual #4 in the pedigree below has an intestinal disease that shows an autosomal recessive mode of inheritance. He marries a woman (#5) who develops Huntington's disease that has an autosomal dominant mode of inheritance. Their son (#6) had Huntington's disease but not the intestinal disorder. Furthermore, the gene that regulates the intestinal disorder is linked to the gene involved in Huntington's disease. (*Note: Individuals with Huntington's disease are shaded grey in the pedigree below; stripes are used to represent the individuals affected by the intestinal disorder. Assume complete penetrance*).



i. Write the genotypes of the following individuals for **both** the disorders (*Note: Use the letters H or h to designate the alleles for the Huntington's disease gene and the letters B or b to designate the alleles of the gene associated with the intestinal disorder. In each case use the uppercase letter for the dominant phenotype and lowercase letter for the recessive phenotype*).

Individuals	Genotypes
#6	HhBb
#7	hhbb

ii. What is the probability that Individual #8 is affected by both disorders, if the genetic distance between the two genes is 10cM?


5%

Her-2 is a gene that encodes a **glycoprotein** that is a member of the family of Epidermal growth factor (EGF) **receptor tyrosine kinases**. Her-2 gene amplification is observed in 30% of breast cancers.

(a) In **a breast cancer patient** that over-expresses Her-2 gene, would you characterize the gene encoding Her-2 protein as an oncogene, tumor suppressor gene or a proto-oncogene? Explain.

It is an oncogene since gene amplification is also a gain of function.

(b) From the choices given below, circle the molecule(s) that may be present in Her-2 receptor glycoprotein.




(c) Breast cancer patients that show the amplification of the Her-2 gene can be effectively treated with Herceptin, a monoclonal antibody that specifically binds to and prevents the dimerization of Her-2 receptors.

i. Based on your knowledge of immunology, each Herceptin antibody molecule can potentially bind to how many Her-2 receptor molecules?

It has **two** antigen binding sites per molecule.

ii. The heavy and the light chains of the Herceptin antibody should join together to form an intact functional antibody. Name the **strongest** type of interaction/bond that holds the chains together to form an antibody. *Disulphide bond*

(d) The following schematic represents the binding of Herceptin to the extracellular domain of the Her-2 receptor. For simplicity only the side- chains of the important amino acids in the binding site are shown. The C^{α} of each amino acids is indicated with an *.



Question 4 continued

Hydrogen

Circle the **strongest interaction** that exists between.....

i. Side-chains of Arg⁵⁰ of Herceptin and Glu⁵⁵⁸ of Her-2 receptor.

Hydrogen Ionic Hydrophobic Interaction Covalent

ii. Backbone of Ser¹⁰³ of Herceptin and side-chain of Thr⁵⁹³ of Her-2 receptor.

Ionic Hydrophobic Interaction Covalent

(e) The Glu⁵⁵⁸ of Her-2 protein is encoded by 5'GAA3' codon. Write down the t-RNA anti-codon for Glu⁵⁵⁸ and label its 5' and 3' ends.

3′CUU5.′

(f) You come across the following mutations of Glu⁵⁵⁸ in the Her-2 gene. For each mutation, explain whether the binding of Herceptin with Her-2 protein will be disrupted. (*Note: A table of 20 essential amino acids and a codon chart is provided on the last two pages of this exam*).

Mutations	Herceptin – Her-2	Explain
	binding (Yes/No?)	
5'GAA3' to 5'UAA3'	No	This mutation creates an early stop codon and hence the
		Her-2 receptor protein will be shorter and most likely non-
		functional. Also Glu ⁵⁵⁸ is needed for herceptin-Her-2
		binding and absence disrupts the binding.
5'GAA3' to 5'GAG3'	Yes	This is a silent mutation that causes no change in the
		amino acid sequence.
5'GAA3' to 5'GAC3'	Yes / No	The Glu ⁵⁵⁸ is changed to Asp that is also negatively
		charged like. But if someone argues that this change may
		charged like. But if someone argues that this change may cause steric hindrance then that is worth full credit.

(g) Below are three different options for a hypothetical linear stretch of amino acids present in the Her-2 receptor. For each option, the amino acids in Region 1 could represent a part of the transmembrane domain that spans the lipid bilayer, and the amino acids in Region 2 represent a part of the cytoplasmic kinase domain.

Region 1Region 2Option 1: lys-cys-gly-ala-val-trp-glu-lys-arg.....

Option 2: leu-ala-gly-cys-ala-val-lys-tyr-glu.....

i. Which option(s) most likely includes a stretch of Her-2 receptor that spans the lipid bilayer? Explain **in one sentence** why you selected this option.


Options 1 and 2 contain a stretch of amino acids stretch that comprises a part of the transmembrane domain is comprised of only the **hydrophobic amino acids** that can span the hydrophobic lipid bilayer.

ii. Which option most likely includes a stretch of Her-2 receptor that can be phosphorylated? Explain **in one sentence** why you selected this option.

Option 2 since it has tyrosine (in the cytosolic domain) that has a side-chain –OH group where a phosphate group can be added.

Consider the following signal transduction pathway that is activated by the binding of EGF ligand to its specific membrane receptor.

- EGF ligand binds to the EGF receptor.
- *Ligand bound EGF receptors become active through phosphorylation and dimerization.*
- Active EGF receptor causes Ras to exchange its bound GDP for GTP and become active.
- Active Ras activates the kinase cascade (RAF, MEK and MAPK) through phosphorylation.
- This increases the expression of *c*-myc gene which **promotes** cell proliferation.



(a) Consider the following cells that have mutations in different components of the EGF signal transduction pathway.


- Mutant 1 (m1): Ras protein that continues to stay in its GDP bound form.
- Mutant 2 (m2): RAF protein that lacks its kinase domain.
- *Mutant 3 (m3): EGF receptor that lacks its extracellular domain.*
- *Mutant 4 (m4): MAPK that is constitutively phosphorylated at its active site.*
- *Mutant 5 (m5): c-myc gene that has a constitutively active promoter.*

Complete the table for each of the following cells. Indicate whether c-myc is expressed and state the change in cell proliferation relative to wild type cells **in the presence of EGF**.

Mutations in	c-myc	Cell proliferation increased//unchanged/ no proliferation? Explain.
the cell	expressed	
	(Yes/No?)	
Wild type	Yes	
Homozygous for m1 and m2	No	No proliferation . Both Ras and Raf kinases are constitutively inactive and so the cascade is never turned on to enhance c-myc gene expression that promotes cell proliferation.
Homozygous for m4 and m5	Yes	<i>Increased proliferation</i> . <i>c-myc will be constitutively expressed owing to its constitutively active promoter irrespective of the presence or absence of active MAPK in nucleus.</i>
Homozygous for m3 and m5	Yes	Increased proliferation. c-myc will be constitutively expressed owing to its constitutively active promoter. This will not require upstream signaling that is initiated by the binding of EGF with its receptor.


Question 5 continued

(b) Shown below is the diagram of the cell cycle and the different phosphorylation states of the rentinoblastoma (Rb) protein. This protein is encoded by a tumor suppressor gene and acts at G1/S phase.



What two **classes** of enzymes can control the phosphorylation of the Rb protein? *Kinases and phosphatases. If a student writes cyclin/cdk or oncoproteins or GF that is worth partial credit.*


(c) You construct a conditional mutant allele of Gene R (R^{ts}), which is active at a low growth temperature but is inactivated by higher (non-permissive) temperature. Using the cells with the R^{ts} mutation, you grow a synchronized cell culture (all cells are growing at same stage of cell cycle and at exactly the same pace) and monitor the DNA content **per cell** over time, with the following results:



- (i) On the diagram above, draw a **box** around one complete cell division cycle at the permissive temperature.
- (ii) Within the box you have drawn, draw vertical lines to separate the phases of the cell cycle, and label each phase using the abbreviations: M, S, G1 and G2.
- (iii) Draw a **star** within the appropriate box marking the phase of the cell cycle in which DNA replication occurs.
- (iv) The vertical arrow on the diagram above indicates the time at which you shifted the cells to the non-permissive temperature. In what phase of the cell cycle is the activity of Gene R required?
 Fither C1 or C1 to S transition phase

Either G1 or G1 to S transition phase

The functional state of G proteins such as Ras depends on their binding to GTP or GDP. The schematic below represents a GTP molecule. GTP is also used to build nucleic acids and as an energy source equivalent to ATP.



(a) Circle the part(s) of this molecule that associates with and activates G proteins.

(b) Draw a box around all the parts of this molecule that are added to the **growing chain** of nucleic acid.

(c) Make a triangle around the **reactive group** that forms a covalent bond with the **incoming base** of a growing nucleic acid polymer.

(d) Name the molecule(s) that are produced from GTP if it is used as an energy source. *GDP+Pi*


(e) Star the atom(s) that can form a hydrogen bond with the complementary nucleotide.

(f) Put an arrow(s) next to the part of this molecule that you would alter if it were to be used as a chain terminator during DNA sequencing. For each arrow, indicate the change you would make. *The OH groups at 2' and 3' carbon position of the ribose sugar of GTP should be changed to deoxy groups.*

(g) The molecule represented in the schematic above can be a direct precursor of...... *Circle all that apply.*



(h) The following diagram represents a complex three-dimensional conformation of a micro RNA (miRNA) molecule.



Question 6 continued

- i. Within Region 2, what bonds/interactions are **primarily involved** in stabilizing the RNA structure? *Hydrogen bonds*.
- ii. In Region 1, if the sequence of the top region is AUGGCUAA, can you predict the % of bases i.e. %A, %U %C and %G of the bottom region? **Explain**. (*Note: Your choices are Yes/ No*).

No since there is no complementary base pairing.

iii. In the Region 2, if the sequence of the top region is AUGGCUAA, can you predict the % of bases i.e. %A, %U %C and %G of the bottom region? **Explain**. (*Note: Your choices are Yes*/*No*).

There is hydrogen bond formation between complementary bases, so we can predict the % of bases as 3/8%U, 4%A, 4%C, 1/%G.

Oncogenic mutations can result from DNA rearrangements or duplications. Below is a partial sequence of two different genes. Gene 1 encodes a protein that is always expressed at high levels. Gene 2 encodes a growth stimulating protein that is only expressed when the cell has received growth promoting signals. On occasion, Gene 2 gets positioned near the promoter for Gene 1. Some of these DNA rearrangements allow an increase in expression of the growth-promoting Gene 2. This can result in uncontrolled cell division. The direction of transcription is shown by an arrow.

Gene 1: expressed at high levels. A Partial sequence of gene 1 is shown below. The italicized and underlined sequence represents the promoter.

	1 10	20	30	40	50	60	70	
	II	1	I		I	-I	I	I
5'	ATCGGTCTCG	GCTACTACGI	AAACGCGCGC	ATATATCGA	TATCTAGCT	AGCTATCGG	ICTCGGCTAC'	TAC
3′	TAGCCAGAGC	CGATGATGCA	TTTGCGCGCG	TATATAGCT	ATAGATCGA	TCGATAGCC	AGAGCCGATG.	ATG
	80	90	100	110	120	130	140	
	I	1	I		I	-I	I	I
5'	GCATGTATCG	ат <u>а</u> таатст <i>а</i>	GCTAGC <u>TTCT</u>	CTTCTCTCI	<u>стссссс</u> бо	GGGGGGCTAG	FACTATGT <u>A</u> T	GGT
3′	CGTACATAGC	TA T ATTAGAT	CGATCG <u>AAGA</u>	GAAGAGAGA	GAGGGGG	CCCCCGATC	ATGATACA T A	CCA
	15	0 160	170	180	190	200	210	
	I	1	I		I	-I	I	I
5'	CGTCTCGGCT	АСТА <u>С</u> СТААА	CGCGCGCATA	TATCGATAT	CTA <u>G</u> CTAGC	TATCGGTCT	CGGCTACTAC	GTA

Gene 2: growth stimulating protein. The following is the portion of gene 2 that is inserted near Gene 1; the bases of one codon are underlined to indicate the reading frame.

- 5' TCTCGGCTACTACGTAAACGCGCGCATATATCGATATCTAGCTACTATCGGTCTCGGCTACTACGTAAAC

You have found four different rearrangements such that:

- 1) Gene 2 sequence inserts immediately after base pair 83 (shown in bold)
- 2) Gene 2 sequence inserts immediately after base pair 136 (shown in bold)
- 3) Gene 2 sequence inserts immediately after base pair 155 (shown in bold)
- 4) Gene 2 sequence inserts immediately after base pair 183 (shown in bold)


(a) Would rearrangement (1) result in an oncogenic mutation? Explain. *No since the insertion is before the ribosomal binding site.*

(b) Would rearrangement (2) result in an oncogenic mutation? Explain. *No since the insertion is not in frame.*

(c) Would rearrangement (3) result in an oncogenic mutation? Explain. *Yes the insertion is in frame.*

(d) Would rearrangement (4) result in an oncogenic mutation? Explain. *No since the insertion is out of frame and results in the production of an early stop codon.*

In nature, the influenza A virus has persisted in wild aquatic birds for millions of years and does not typically produce harmful effects. This is a single (-) stranded, segmented, RNA virus that does not replicate via a DNA intermediate. Its genome is comprised of 8 distinct RNA strands that together encode 10 different proteins. The following is a schematic of the influenza virus.



(a) Influenza virus is unable to make more viral RNA genome within the host cells using exclusively the host cell proteins.

i. Explain why that is so.

This being a negative(-) stranded RNA virus can not be converted by the host cell machinery to a positive (+) RNA that has the same polarity as mRNA and is needed for translation.

ii. Explain how the virus overcomes this issue and replicates its genome in the host. It solves this problem by **bringing along its own RNA dependant RNA polymerase enzyme** at the time of infection. Also RNA is less stable than DNA due to the presence of extra –OH group at 2'C position of ribose sugar.

(b) Explain why the influenza A virus can rapidly mutate to produce new variants. *The RNA dependant* **RNA polymerase has no proofreading activity** *thus increasing the frequency of mutation that leads to the production of new strains.*

(c) You decide to generate vaccine against Influenza A virus using either a live-attenuated form of the virus or heat–killed viral particles.

i. Which of these two vaccine strategies produces both antibody and Tc mediated immune responses? Explain why.

Live-attenuated form of virus will produce both the responses. The virus is still replicating although at a very slow pace and hence the viral proteins can presented on the surface of infected cells through MHC1 leading to a Tc mediated cell killing or through MHC-II by Antigen presenting cells leading to a T_H and B cell mediated humoral immune response.

ii. If the vaccine generated against the virus leads to a cell mediated immune response, name the proteins/enzymes (secreted by the cytotoxic T cells) that cause the killing of virus infected cells and propose a mechanism through which they do so.

Perforins that kill the virus infected cells by **creating holes and making it leaky**. **Granzymes** that **promote apoptosis** of virus infected cells

- iii. If the vaccine generated results only in a humoral response and production of antibodies....
 - Identify the most likely components of the virus, from the diagram provided at the beginning of this question, to which the raised antibodies will bind.

Hemagglutinin (HA) and neuraminidase (NA) since these are exposed at the viral surface.

Question 8 continued

• Propose a mechanism through which the **secreted antibodies** can counteract the viral infection.

The secreted antibodies can bind to antigens located at the viral surface. Thus the virus gets coated by the antibodies and in this form it can be engulfed and digested by macrophage. This process is also called opsonization.

(d) If an individual is exposed a second time to same strain of Influenza A virus, the secondary immune response observed is much faster and stronger than the primary response. Propose **an explanation** for an increase in the rate and strength of the secondary immune response.

The individual already has **the memory** T_H and memory *B* cells that were produced during the primary exposure. These cells can proliferate to produce more memory cells and the plasma cells that produce and secrete antibodies which lead to humoral immune response.

(e) Pigs can be infected both by the avian and human forms of the Influenza virus. This allows them to act as virus mixing bowls in which the two viral strains can readily exchange RNA strands. Thus the virus that emerges from such double-infected species can represent a unique assortment of genes, generating new strains of virus. The HIN1 virus that causes Swine flu is one such example. Why is a newly emerged virus considered a threat that is significant enough to cause a global pandemic, compared to a seasonal viral strain?

Newly emerged virus may have surface antigens which have never been encountered by the immune system of the human population. This may therefore cause a global pandemic.

(f) You come across a patient who is suffering from a mysterious illness that kills the brain cells. You grind the damaged brain cells and treat them separately **in vitro** with DNAse, RNAse, proteases and UV. You use the treated samples to infect normal mice. You observe that all these samples, except the one treated with proteases, can cause the same illness in infected mice. Based on the data provided, what is the most likely cause of this illness?

This disease is caused by an *infectious protein particle* that are often called *prions*.

You have started up a company to produce a vaccine against a particular DNA virus that causes disease in humans. To begin with, you want to screen the viral genes to identify those which encode proteins that can be used as potential antigens to create this vaccine.

You intend to adopt the following strategy to identify such genes:

- Isolate the viral genome.
- Digest the genome using a specific restriction enzyme.
- Clone the digested viral DNA fragments into a specific cloning vector to make a genomic library.
- *In bacterial cells, select a clone producing viral antigen from viral gene(s).*

(a) Why would you make a viral genomic library, rather than a cDNA library, to screen for viral genes?

The cDNA library is prepared from mature mRNA (that have no introns but only exons) and is used to look for those genes that are specifically expressed in a cell. However, this is not required in the viruses since they have no introns. Their mRNA can be directly translated into proteins or polyproteins without any need for splicing. A cDNA library made from a virus infected cell is a library of genes expressed in the cell will include not only viral genes but also cellular genes (and a lot more cellular genes than viral ones) and would therefore be useless in trying to make a viral DNA library.

(b) Shown below are the restriction sites for four restriction enzymes. *Cutting sites are indicated by a slash* (/).

<u>Enzyme X</u>	<u>Enzyme Y</u>	<u>Enzyme Z</u>	<u>Enzyme R</u>
5'-CC/CG GG-3'	5'-TC/CG GA-3'	5'-T/TCGA A-3'	5'-TCC/GGG-3'
3'-GG GC/CC-5'	3'-AG GC/CT-5'	3'-A AGCT/T-5'	3′-AGG/CCC-5′

Usually, fragments cut with different restriction enzymes cannot be ligated together. However, DNA fragments cut with enzyme X and enzyme Y can be ligated together.


i. Based on the sequences given above, write the 6-base pair sequence of the doublestranded DNA molecule at the site of ligation of an X-cut DNA fragment to a Y-cut DNA fragment. Be sure to indicate the 5' and 3' ends of each DNA strand.

5'CCCGGA3'	or	5'TCCGGG3'
3'GGGCCT5'		3'AGGCCC5'

- ii. Will the resulting sequence be cut by..... *circle 'Yes' or 'No' for each:*
 - Restriction enzyme X (Yes (No))
 - Restriction enzyme Y (Yes(No)
 - Restriction enzyme Z (Yes(No)
 - Restriction enzyme R (Yes/No)

Question 9 continued

(c) You will use one of the three plasmids shown in the schematic below as the cloning vector to make your library. Assume that you would clone fragments of the viral DNA into the restriction site X. You plan to select the transformed bacteria on Tetracycline media. **Circle** the best choice of vector for your experiment. **Explain** why you selected this option.



The plasmid needs a bacterial origin of replication so that it can replicate in bacteria (this feature is absent in plasmid #3). It also needs the **Tetracyclin resistant gene that has no recognition site for the restriction** *enzyme X* (unlike that observed in plasmid #1). Therefore plasmid #2 is the best option.


(d) After you have transformed *E. coli* cells with your library, you grow them on media containing Tetracycline to select for the bacterial cells that have been transformed. What additional selective media would you replica-plate these colonies onto to identify the clones that contain viral DNA?

Ampicillin containing medium.

(e) After various DNA based assays, you identify one colony that contains a gene which encodes a viral protein to use as the basis of your vaccine. You decide to express it in the milk of transgenic cows in order to produce it in large quantities. You need to fuse the viral gene to a cow-specific promoter so it will be expressed in the cow cells. For the promoter you choose, under what condition(s) and in what cell type(s) should the promoter be active? **Explain**.

You would select a mammary gland specific which is active (expresses protein) in the mammary gland constitutively, so that the protein will be expressed in the cow's milk and will always be produced.

(f) You transfer the viral gene into a new plasmid vector to introduce it into cow cells. From the choices below...




i. Which of the above vectors could you use to maintain and express the viral gene in cow cells? #5

Question 9 continued

ii. One way to make your transgenic cow is to have the viral gene insert into the cow genome. If you are employing this approach and do **not** want the original plasmid vector to be maintained in the cow, which vector could you use? **#6**

(g) You introduce the recombinant vector into embryonic cow cells in culture. Before you start growing up transgenic cows, you decide to check the sequence of the transgene in the cells to make sure it is correct. You will first PCR amplify your gene of interest, then **sequence the PCR product**. You have three primers which anneal to your DNA construct as diagrammed below:



From the list below, check each item to indicate which reaction(s), if any, it should be added to.

Reagents	PCR amplification	DNA sequencing
Primer #1	X	X or #3
Primer #2		
Primer #3	X	X or #1
DNA polymerase	X	X
dNTPs mix	X	X
ddNTP		X
Genomic DNA from transgenic cow cell	X	
Reverse transcriptase		

(h) Finally, you use specific antibodies to purify the viral protein from the cow's milk. **Circle** the part(s) of the antibody which will bind to the viral protein.


Heavy chain

Light chain

Constant region

Variable region

An important set of neural connections is between motor neurons of the spinal cord and their target muscles in the limbs. Lateral neurons express the transcription factor **LIM-1** and the receptor tyrosine kinase **EPH-4**, and innervate (grow towards and create synapses with) dorsal limb muscles. In contrast, medial neurons express the transcription factor **ISL-1**, do not express EPH-4, and innervate the ventral limb muscles. Both dorsal and ventral limb muscles express and secrete **ephrin-4**, the ligand for the EPH-4 receptor.



(a) In order to ask whether LIM-1 and ISL-1 play a role in axonal pathfinding, researchers introduced a LIM-1 expressing construct into developing medial neurons. The resulting neurons expressed EPH-4 and innervated dorsal limb muscle rather than ventral. Conversely, expressing ISL-1 in lateral neurons prevented LIM-1 and EPH-4 expression, and the resulting neurons innervated ventral muscle, rather than dorsal muscle. Diagram the regulatory relationships between **EPH-4**, **LIM-1**, **ISL-1**, and **dorsal muscle innervation** that you can derive from these results. In your diagram, use an \rightarrow to indicate that it activates and a \perp to indicate inhibition.

There are two possibilities:


 $ISL-1 \longrightarrow LIM-1 \longrightarrow EPH-4 \qquad Or \qquad ISL-1 \longrightarrow LIM-1 \longrightarrow EPH-4$

In either case, EPH-4 promotes dorsal muscle innervation.

(b) Axon pathfinding takes place in immature neurons. Once axons find their targets on the muscle, chemical synapses form to create the neuromuscular junctions. In the term **chemical synapse**, to what class of molecules does "chemical" refer? *Neurotransmitter*.

Question 10 continued

In neuromuscular synapses, the axon is presynaptic and the muscle is postsynaptic. Neuromuscular synapses are often excitatory, and the output is muscle contraction. The neurotransmitter is acetylcholine (Ach), and binds to nicotinic acetylcholine receptors (AchR), which are **ligand-gated Na+ channels**. Ach is destroyed by acetylcholinesterase (Ach-esterase) after it is released into the synaptic cleft.



(c) In Myasthenia gravis, that targets the Ach receptor, muscles fail to contract, leading to profound weakness. Explain **one type of change** in Ach receptor that could cause this disorder, and why.

Any loss of function (i.e. blocking Ach receptor binding site, conformation change etc) in the gene encoding for the Ach receptor can cause this disorder by preventing muscle from receiving the signal (from pre-synaptic neuron) so that it can contract.

(d) Lambert-Eaton syndrome is associated with the production of antibodies to pre-synaptic voltagegated calcium channels. Explain why such antibodies cause a decrease in muscle contraction in affected individuals relative to normal individuals.

The antibodies will prevent calcium influx through voltage gated calcium channels that will cause **the failure of vesicles to fuse with the plasma membrane and release the Ach in the synaptic cleft** leading to decreased or no muscle contraction.


(e) Botulism is an illness caused by Botulinum toxin, produced by the bacterium Clostridium botulinum. The toxin inactivates synaptobrevin, a membrane protein of synaptic vesicles, required for exocytosis. Would the frequency of muscle contraction increase or decrease in patients with Botulism relative to unaffected individuals? Explain.

The muscle contraction will **decrease** since **exocytosis of vesicles is required for the release of Ach in the synaptic cleft** which binds to its specific Ach receptors located on muscles to trigger muscle contraction

(f) Dementia with Lewy Bodies (DLB) is a major cause of senile dementia, similar to Alzheimers. The disorder can be treated with Acetylcholinesterase, and Ach receptors are normal in these patients. What is the most likely cause of DLB?

It is either an increased release of Ach by the presynaptic neurons or a defective acetylcholinesterase enzyme that fails to digest the Ach that has been released in the synaptic cleft.

The liver is an organ which consists of lobules, each containing three major cell types in characteristic organization. The most prevalent type of cells are **hepatocytes**, which filter the blood, **endothelial cells** which line the sinusoids, vessels that carry blood between groups of hepatocytes, and a few **Kupfer cells** which also line the sinusoids.



HepaHope is a bioengineering company that is testing a "hybrid" liver. This consists of a suspension of single hepatocytes on a synthetic support. It works like a kidney dialysis machine, filtering the patient's blood to remove ammonia and detoxify wastes. One issue with this device is that the hepatocytes constantly need replenishing, as they stop functioning about 24 hours after being added to the device.

(a) In general what structural aspect of the normal liver is missing from the HepaHope device? *The complex* **3D***-conformation and the surrounding niche is missing*.

(b) You consult with the company and suggest that hepatocyte function may be prolonged by addition of signaling molecules. You decide to test ligands from four major signaling pathways to see if they prolong liver cell function. These ligands are Fgf3, Delta, Wnt8 and BMP4. Factors are tested in combination, with the encouraging results below.

couraging results below.				
Factor	Hepatocyte Function (hours)			
No factors	24			
All four factors	72			
BMP+Wnt8+Fgf	72			
BMP+Fgf+Delta	24			
Wnt8+Fgf+Delta	72			

i. Which ligand(s) is most important in prolonging the liver function? What next factor combination(s) would you assay to test the ligands that you identified?

Wnt 8 appears to be essential either alone or in combination with Fgf. One may assay wnt8 alone, compred with wnt8+Fgf, to determine whether Fgf is required.

ii. If any of these ligands normally regulate liver function (that is, in the intact liver), where would you expect to observe expression of (*Your choices are hepatocytes, endothelial cells, kupfer cells and sinusoids*).

Question 11 continued

- These ligands? *Endothelial cells, Kupfur cells or Sinusoids* (any answer is fine based on the provided information).
- The receptors for these ligands? *Hepatocytes*

(c) Hepatocytes have a half-life (time of survival) of about 10 days. BrdU is a thymine analog that is incorporated normally into DNA, but is used in a pulse/chase assay to distinguish DNA synthesized during the pulse. Describe a pulse/chase experiment with BrdU that would measure hepatocyte half-life.

BrdU incorpration over time to assay for hepatocytes cell death.

(d) Damaged liver can regenerate well, suggesting the involvement of liver stem cells. Some evidence suggests that that Kupfer cells are liver stem cells. How would you test whether Kupfer cells are stem cells, using a transplant approach? *Note: Carbon tetrachloride treatment can be used to specifically destroy the liver.*

Destroy the liver cells of a mouse using carbon tetrachloride. Transplant Kupfer cells from a healthy liver into the mouse. If the Kupfer cells are stem cells, liver will be able to regenerate and mouse will be OK.

(e) The sinusoids are tubes that arise from single cells that associate to form a sheet which eventually forms a tube. What is the term for conversion of single cells to cell sheets?

Mesenchymal to epithelial transition.


(f) What changes will the following perturbations have on single cells versus cell sheets? *Your options are: death; adhesion; movement; shape; no change.* For each perturbation, select the most likely option(s) and explain your choice.

Perturbation	Effect on		Explanation
	Single cell	Cell sheet	
Removal of extracellular matrix	Shape, movement	Adhesion	ECM has ligands that may be involved in triggering the signaling pathways that regulate shape and movement of mesenchymal cells or adhesion of epithelial cells.
Tight junction disruption	No change	Adhesion	These are involved in holding the epithelial cells of the sheet together.
Actin depolymerization	Shape, movement	Shape	Actin is a cytoskeletal protein that exists in the form of G monomers that can polymerize to form F actin polymer. his polymerization regulates shape and movement of cells.
Prevention of homotypic adhesion	No change	Adhesion	Homotypic cell-cell adhesion is involved allows the epithelial cells to adhere together and form a sheet. If this is disrupted the epithelial cell shhet falls apart and most likely these cells undergo a transition to mesenchymal cells.
Stabilization of microtubules	Shape and movement	No change	Microtubules are required for contraction and movement and hence mesencyhmal cells will be influenced.

(a) The liver arises from ventral embryonic endoderm. Using some or all of the frog embryos below, how would you use the technique of fate mapping to address from where in the embryo the liver arises?



Early embryo (4 hours old)



0 hrs embryo Older embryo (40 hours)

Inject a non-diffusible dye into the cells located in different cells of early embryo and see if the liver cells in the 40 hrs embryo retain that dye.

(b) Hepatocytes are differentiated liver cells. **HNF4a is a hepatocyte-specific transcription factor necessary for activation of all liver differentiation genes, including albumin.** In order to understand the mechanism by which HNF4a acts, you express HNF4a in the developing pancreas, which is also derived from endoderm. In this case, expression of albumin and other liver-specific genes is not activated. Explain this observation.

HNF-4 is functional only in the cells that are committed to become liver cells. It does not activate albumin in pancreatic cells. It is also possible that the developing pancreas expresses a protein that acts as an inhibitor of HNF-4.

(c) DNMT is a DNA methylase, expressed throughout development, which adds methyl groups to cytosine. You decide to regenerate animals by SCNT using the nuclei either from adult hepatocytes, 40 hour embryonic hepatocytes, or 40 hour hepatocytes treated with an inhibitor of the DNA methlyase DNMT. Which of the three nuclei would be the best choice? Explain why you would prefer one over the other.

40 hour hepatocytes treated with an inhibitor of the DNA methlyase DNMT will be the best choice. Since the methylation pattern are important for proper gene regulation and should be as close to the early embryonic state as possible for successful regeneration of animals by SCNT.

7.013 Introductory Biology Spring 2013

For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.